178 lines
37 KiB
Text
178 lines
37 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK595844">
|
|
<meta name="ncbi_domain" content="livertox">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK595844/?report=reader">
|
|
<meta name="ncbi_pagename" content="Anifrolumab - LiverTox - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Anifrolumab - LiverTox - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/livertox/ACEinibitors/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/livertox/AntihelminthicAgents/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/livertox/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]">
|
|
<meta name="citation_title" content="Anifrolumab">
|
|
<meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="citation_date" content="2023/09/20">
|
|
<meta name="citation_pmid" content="37824693">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK595844/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Anifrolumab">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="DC.Date" content="2023/09/20">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK595844/">
|
|
<meta name="description" content="Anifrolumab is a human monoclonal antibody to the type 1 interferon receptor which is used in the therapy of moderate-to-severe systemic lupus erythematous. Anifrolumab has been linked to a low incidence of transient serum enzyme elevations during therapy and has not been linked to instances of clinically apparent liver injury.">
|
|
<meta name="og:title" content="Anifrolumab">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Anifrolumab is a human monoclonal antibody to the type 1 interferon receptor which is used in the therapy of moderate-to-severe systemic lupus erythematous. Anifrolumab has been linked to a low incidence of transient serum enzyme elevations during therapy and has not been linked to instances of clinically apparent liver injury.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK595844/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/livertox/Anifrolumab/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK595844/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8E179A7D7B6C110000000000AC0092.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK595844/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/livertox/ACEinibitors/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Anifrolumab</div><div class="j">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</div></div><div class="tail"><a href="/books/n/livertox/AntihelminthicAgents/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK595844/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK595844/&text=Anifrolumab"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/livertox/?report=reader">Title Information</a><a href="/books/n/livertox/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK595844/?report=classic">Switch to classic view</a><a href="/books/NBK595844/pdf/Bookshelf_NBK595844.pdf">PDF (90K)</a><a href="/books/NBK595844/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK595844%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8E179A7D7B6C110000000000AC0092.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK595844_"><span class="title" itemprop="name">Anifrolumab</span></h1><p class="fm-aai"><a href="#_NBK595844_pubdet_">Publication Details</a></p></div></div><div class="body-content whole_rhythm" itemprop="text"><div id="Anifrolumab.OVERVIEW"><h2 id="_Anifrolumab_OVERVIEW_">OVERVIEW</h2><div id="Anifrolumab.Introduction"><h3>Introduction</h3><p>Anifrolumab is a human monoclonal antibody to the type 1 interferon receptor which is used in the therapy of moderate-to-severe systemic lupus erythematous. Anifrolumab has been linked to a low incidence of transient serum enzyme elevations during therapy and has not been linked to instances of clinically apparent liver injury.</p></div><div id="Anifrolumab.Background"><h3>Background</h3><p>Anifrolumab (an” i frol’ ue mab) is a human monoclonal IgG1 antibody to the type 1 interferon (IFN) receptor subunit 1 which is used to treat adults with moderate-to-severe systemic lupus erythematosus (SLE). Anifrolumab binds to type 1 interferon receptors blocking their activation and induction of interferon related genes. This monoclonal antibody has been shown to be effective in reducing disease activity in patients with systemic lupus erythematosus, a disease marked by elevated levels of soluble interferon gene induced proteins with immune dysregulation and production of pathogenic autoantibodies and immune complexes. Anifrolumab was approved for use in the United States in 2021 and current indications are for treatment of adult patients with active, autoantibody positive systemic lupus erythematosus (SLE) who are receiving standard therapy. Its beneficial effects have not been demonstrated in patients with severe lupus nephritis or central nervous system involvement. Anifrolumab is available under the brand name Saphnelo in single dose vials of 300 mg in 2 mL. The recommended dose is 300 mg given as an intravenous infusion (over 30 minutes) every 4 weeks. Adverse effects include infusion reactions, upper respiratory symptoms and infections, bronchitis, cough, and herpes zoster. Rare but potentially serious side effects include severe hypersensitivity reactions (angioedema or anaphylaxis), severe infections, and possibly malignancies. The potential of reactivation of latent infections such as tuberculosis and hepatitis B from anifrolumab is not clear. Patients receiving anifrolumab should not receive live viral vaccines.</p></div><div id="Anifrolumab.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In preregistration controlled trials, elevations in serum aminotransferase levels were uncommon (less than 1%) and no more frequent during anifrolumab than with placebo therapy. Elevations in aminotransferase levels above 5 times the ULN were less common on anifrolumab than placebo therapy, and there were no reports of clinically apparent liver injury attributed to anifrolumab. Since its approval and more widescale use, there have been no case reports of liver injury with jaundice linked to anifrolumab therapy. Reactivation of hepatitis B as well as immune-mediated hepatitis can occur with use of immunosuppressive monoclonal antibodies such as infliximab and adalimumab, but instances have not been reported with anifrolumab.</p><p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p></div><div id="Anifrolumab.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>There is little evidence that anifrolumab is a cause of liver injury, and mechanisms by which it occurs is not clear but might result from immune modulation.</p></div><div id="Anifrolumab.Outcome_and_Management"><h3>Outcome and Management</h3><p>The serum aminotransferase elevations that have been reported during anifrolumab therapy were generally transient, mild and asymptomatic and did not require dose modification or delay in therapy. Elevations above 5 times the upper limit of normal should lead to more careful monitoring and suspension of further infusions, at least until levels return to normal or near normal levels. There is no evidence of cross sensitivity to hepatic reactions among the various monoclonal antibodies.</p><p>Drug Class: <a href="/books/n/livertox/MonoclonalAntibodies/?report=reader">Monoclonal Antibodies</a>, Immunosuppressive Agents</p><p>Other Drugs for Systemic Lupus Erythematosus: <a href="/books/n/livertox/Belimumab/?report=reader">Belimumab</a></p></div></div><div id="Anifrolumab.PRODUCT_INFORMATION"><h2 id="_Anifrolumab_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Anifrolumab – Saphnelo®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Immunosuppressive Agents</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?label=all&query=Anifrolumab" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Anifrolumab.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Anifrolumab_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figAnifrolumabTc"><a href="/books/NBK595844/table/Anifrolumab.Tc/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figAnifrolumabTc" rid-ob="figobAnifrolumabTc"><img class="small-thumb" src="/books/NBK595844/table/Anifrolumab.Tc/?report=thumb" src-large="/books/NBK595844/table/Anifrolumab.Tc/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Anifrolumab.Tc"><a href="/books/NBK595844/table/Anifrolumab.Tc/?report=objectonly" target="object" rid-ob="figobAnifrolumabTc">Table</a></h4></div></div></div><div id="Anifrolumab.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Anifrolumab_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 20 September 2023</p><p>Abbreviations: PML, progressive multifocal leukoencephalopathy; SLE, systemic lupus erythematosus.</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Anifrolumab.REF.zimmerman.1999">Zimmerman HJ. Drugs used to treat rheumatic and musculospastic disease. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 517-54.<div><i>(Expert review of hepatotoxicity published in 1999, before the availability of most monoclonal antibody therapies).</i></div></div></li><li><div class="bk_ref" id="Anifrolumab.REF.reuben.2011">Reuben A. Hepatotoxicity of immunosuppressive drugs. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2011, pp. 569-91.<div><i>(Review of hepatotoxicity of immunosuppressive agents does not mention anifrolumab).</i></div></div></li><li><div class="bk_ref" id="Anifrolumab.REF.krensky.2018">Krensky AM, Azzi JR, Hafler DA. Immunosuppressants and toleragens. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 637-53.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Anifrolumab.REF.fda">FDA: <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761123Orig1s000MultidisciplineR.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.accessdata<wbr style="display:inline-block"></wbr>​.fda.gov/drugsatfda_docs<wbr style="display:inline-block"></wbr>​/nda/2021/761123Orig1s000MultidisciplineR.pdf</a><div><i>(FDA website with product labels and initial multidiscipline clinical review of the safety and efficacy of anifrolumab based on results from 1,123 adults treated in 3 controlled trials, stated that the safety results were generally favorable with adverse events reported in 87% of anifrolumab vs 79% of placebo recipients, and serious adverse events in 12% vs 17% including serious infections in 4.8% vs 5.6%, herpes zoster in 12% vs 3%, hypersensitivity reactions in 2.6% vs 0.6%, and ALT elevations above 5 times ULN in 0.3% vs 0.8%).</i></div></div></li><li><div class="bk_ref" id="Anifrolumab.REF.furie.2017.376">Furie
|
|
R, Khamashta
|
|
M, Merrill
|
|
JT, Werth
|
|
VP, Kalunian
|
|
K, Brohawn
|
|
P, Illei
|
|
GG, et al.; CD1013 Study Investigators. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.
|
|
Arthritis Rheumatol.
|
|
2017;69:376-386. [<a href="/pmc/articles/PMC5299497/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5299497</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28130918" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28130918</span></a>]<div><i>(Among 305 adults with SLE treated with anifrolumab [300 or 1000 mg] vs placebo every 4 weeks for 52 weeks, clinical responses occurred in 63% and 54% vs 40%, while adverse event rates were higher with the higher dose including herpes zoster in 5.2% and 9.5% vs 2%; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Anifrolumab.REF.morand.2020.211">Morand
|
|
EF, Furie
|
|
R, Tanaka
|
|
Y, Bruce
|
|
IN, Askanase
|
|
AD, Richez
|
|
C, Bae
|
|
SC, et al.; TULIP-2 Trial Investigators. Trial of anifrolumab in active systemic lupus erythematosus.
|
|
N Engl J Med.
|
|
2020;382:211-221. [<a href="https://pubmed.ncbi.nlm.nih.gov/31851795" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31851795</span></a>]<div><i>(Among 362 adults with SLE treated with anifrolumab vs placebo, response rates at 52 weeks was 48% vs 32% and adverse events 88% vs 84%, serious adverse events 8% vs 17%, herpes zoster 7.2% vs 1.1%, serious infections 2.8% vs 5.5%, and infusion reactions 14% vs 8%; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Anifrolumab.REF.smith.2020.4462">Smith
|
|
MA, Chiang
|
|
CC, Zerrouki
|
|
K, Rahman
|
|
S, White
|
|
WI, Streicher
|
|
K, Rees
|
|
WA, et al.
|
|
Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus.
|
|
Sci Rep.
|
|
2020;10:4462. [<a href="/pmc/articles/PMC7064569/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7064569</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32157125" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32157125</span></a>]<div><i>(Among 1,132 protein measurements from blood samples from patients with SLE, type 1 interferon induced genes were often elevated and patients could be categorized by high vs low levels).</i></div></div></li><li><div class="bk_ref" id="Anifrolumab.REF8">Anifrolumab (Saphnelo) for systemic lupus erythematosus.
|
|
Med Lett Drugs Ther.
|
|
2021;63(1633):146-147. [<a href="https://pubmed.ncbi.nlm.nih.gov/34550961" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34550961</span></a>]<div><i>(Concise review of the mechanism of action, clinical efficacy, safety, and costs of anifrolumab shortly after its approval as therapy of SLE in the US, discusses adverse events of upper respiratory infections, bronchitis, infusion reactions, herpes zoster, and cough, but does not mention ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Anifrolumab.REF.chatham.2021.816">Chatham
|
|
WW, Furie
|
|
R, Saxena
|
|
A, Brohawn
|
|
P, Schwetje
|
|
E, Abreu
|
|
G, Tummala
|
|
R. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase I open-label extension study.
|
|
Arthritis Rheumatol.
|
|
2021;73:816-825. [<a href="/pmc/articles/PMC8252065/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8252065</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33225631" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33225631</span></a>]<div><i>(Among 218 adult participants with SLE in controlled trials of anifrolumab who were enrolled in an open label extension study, clinical responses were sustained, no new safety signals were observed and there were no liver related serious adverse events).</i></div></div></li><li><div class="bk_ref" id="Anifrolumab.REF.jayne.2022.496">Jayne
|
|
D, Rovin
|
|
B, Mysler
|
|
EF, Furie
|
|
RA, Houssiau
|
|
FA, Trasieva
|
|
T, Knagenhjelm
|
|
J, et al.
|
|
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.
|
|
Ann Rheum Dis.
|
|
2022;81:496-506. [<a href="/pmc/articles/PMC8921596/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8921596</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35144924" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35144924</span></a>]<div><i>(Among 147 adults with active lupus nephritis treated with standard therapy and anifrolumab [300 mg every 4 weeks or an intensive early regimen] or placebo, clinical response rates were similar among the three groups while herpes zoster was more frequent with anifrolumab [17% vs 8%]; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Anifrolumab.REF.kalunian.2023.253">Kalunian
|
|
KC, Furie
|
|
R, Morand
|
|
EF, Bruce
|
|
IN, Manzi
|
|
S, Tanaka
|
|
Y, Winthrop
|
|
K, et al.
|
|
A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus.
|
|
Arthritis Rheumatol.
|
|
2023;75:253-265. [<a href="/pmc/articles/PMC10098934/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10098934</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36369793" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36369793</span></a>]<div><i>(Among 560 adults with SLE enrolled in a long term extension study of anifrolumab [300 mg every 4 weeks], adverse events occurred in 93% which were scored as serious in 26%, herpes zoster in 13% and severe infections in 10%, 1 case of anaphylaxis, and 12 malignancies; no mention of ALT elevations or hepatoxicity and no cases of active tuberculosis).</i></div></div></li><li><div class="bk_ref" id="Anifrolumab.REF.neupane.2023.e000907">Neupane
|
|
B, Shukla
|
|
P, Slim
|
|
M, Martin
|
|
A, Petri
|
|
M, Bertsias
|
|
GK, Kim
|
|
AHJ, et al.
|
|
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks.
|
|
Lupus Sci Med.
|
|
2023;10:e000907. [<a href="/pmc/articles/PMC10186457/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10186457</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37147022" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37147022</span></a>]<div><i>(Analysis of 5 trials of belimumab and 3 of anifrolumab in adults with moderate-to-severe SLE found similar rates of clinical response to both agents; no analysis of adverse events).</i></div></div></li><li><div class="bk_ref" id="Anifrolumab.REF.kalunian.2023.253_1">Kalunian
|
|
KC, Furie
|
|
R, Morand
|
|
EF, Bruce
|
|
IN, Manzi
|
|
S, Tanaka
|
|
Y, Winthrop
|
|
K, et al.
|
|
A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus.
|
|
Arthritis Rheumatol.
|
|
2023;75:253-265. [<a href="/pmc/articles/PMC10098934/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10098934</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36369793" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36369793</span></a>]<div><i>(Among 560 adults with SLE enrolled in a long term extension study of anifrolumab [300 mg every 4 weeks], adverse events occurred in 93% which were scored as serious in 26%, herpes zoster in 13% and severe infections in 10%, 1 case of anaphylaxis, and 12 malignancies; no mention of ALT elevations or hepatoxicity and no cases of active tuberculosis).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK595844_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">September 20, 2023</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Anifrolumab. [Updated 2023 Sep 20].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/livertox/ACEinibitors/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/livertox/AntihelminthicAgents/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobAnifrolumabTc"><div id="Anifrolumab.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK595844/table/Anifrolumab.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Anifrolumab.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Anifrolumab.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Anifrolumab.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NO.</th><th id="hd_h_Anifrolumab.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Anifrolumab.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Anifrolumab.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anifrolumab</td><td headers="hd_h_Anifrolumab.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/249565938" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">1326232-46-5</a>
|
|
</td><td headers="hd_h_Anifrolumab.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Monoclonal Antibody</td><td headers="hd_h_Anifrolumab.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not Available</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|